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Very few efforts have been undertaken to scale-up low-cost approaches to cervical cancer
prevention in low-resource countries.
Methods
In a public sector cervical cancer prevention program in Zambia, nurses provided visual-in-
spection with acetic acid (VIA) and cryotherapy in clinics co-housed with HIV/AIDS pro-
grams, and referred women with complex lesions for histopathologic evaluation. Low-cost
technological adaptations were deployed for improving VIA detection, facilitating expert
physician opinion, and ensuring quality assurance. Key process and outcome indicators
were derived by analyzing electronic medical records to evaluate program
expansion efforts.
Findings
Between 2006-2013, screening services were expanded from 2 to 12 clinics in Lusaka, the
most-populous province in Zambia, through which 102,942 women were screened. The ma-
jority (71.7%) were in the target age-range of 25–49 years; 28% were HIV-positive. Out of
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101,867 with evaluable data, 20,419 (20%) were VIA positive, of whom 11,508 (56.4%)
were treated with cryotherapy, and 8,911 (43.6%) were referred for histopathologic evalua-
tion. Most women (87%, 86,301 of 98,961 evaluable) received same-day services (includ-
ing 5% undergoing same-visit cryotherapy and 82% screening VIA-negative). The
proportion of women with cervical intraepithelial neoplasia grade 2 and worse (CIN2+)
among those referred for histopathologic evaluation was 44.1% (1,735/3,938 with histopa-
thology results). Detection rates for CIN2+ and invasive cervical cancer were 17 and 7 per
1,000 women screened, respectively. Women with HIV were more likely to screen positive,
to be referred for histopathologic evaluation, and to have cervical precancer and cancer
than HIV-negative women.
Interpretation
We creatively disrupted the 'no screening' status quo prevailing in Zambia and addressed
the heavy burden of cervical disease among previously unscreened women by establishing
and scaling-up public-sector screening and treatment services at a population level. Key de-
terminants for successful expansion included leveraging HIV/AIDS program investments,
and context-specific information technology applications for quality assurance and filling
human resource gaps.
Introduction
A high incidence of invasive cervical cancer (ICC) is observed in low- and middle-income
countries (LMICs) where high quality prevention services are unavailable or inaccessible,
awareness about cancer risk is low, healthcare infrastructures are fragmented and dysfunction-
al, lack of appropriate public health policies and competing priorities detract from making sub-
stantive improvements to the status quo [1–4]. While cytology-based screening has been the
cornerstone for secondary prevention of cervical cancer in most high-income countries, it re-
mains unavailable or difficult to implement in most resource-constrained settings. Multiple in-
ternational efforts have been undertaken to develop cost-effective and sustainable alternatives.
Screening with visual inspection of the cervix with acetic acid (VIA) has received the most at-
tention globally primarily because of its low cost and facilitation of immediate decisions about
treatment (cryotherapy) or referral [5–7]. Observational studies, field demonstration projects
and randomized trials have shown that VIA screening can be effective in reducing the inci-
dence and mortality due to ICC [8–10]. Although human papillomavirus (HPV)-based screen-
ing is more sensitive and effective than either VIA or cytology [11–13], low-cost and single-
visit point-of-care HPV screening assays are not yet widely available, and HPV-positive results
invariably need triage by visual screening methods in LMICs [14,15], underscoring the impor-
tance of VIA-based cervical cancer screening platforms.
In 2013, the World Health Organization (WHO) endorsed the use of VIA and cryotherapy-
based ‘screen-and-treat’ programs in countries without existing cervical cancer services [15].
Yet, several research questions related to implementation of VIA remain, particularly when it
is adopted as part of routine health care systems. Are such services scalable at a population-
level? Is integration with other vertical disease control programs, such as those for human
immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) control, practi-
cal? Can such screening be implemented in countries with high HIV prevalence? Can
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operational efficiency be measured through programmatic process and outcome metrics? Can
setting-specific challenges in implementation be overcome with locally-developed solutions?
We sought to answer these implementation research questions by conducting an evaluation
of the Cervical Cancer Prevention Program in Zambia (CCPPZ), a public-sector program initi-
ated in 2006 that has provided services (as of March 2015) to over 200,000 women using a lo-
cally contextualized intervention with simultaneous health system strengthening. This effort
represents the largest such national-level initiative and offers a model for scaling-up of cervical
cancer prevention services in sub-Saharan Africa and globally.
Methods
Setting and Context
Zambia has some of the world’s highest rates of ICC incidence (58.4/100,000 per year) and
mortality (36.2/100,000 per year) rates. ICC is the most commonly diagnosed malignancy
among the country’s adult population (both sexes combined), and accounts for more than one-
third of annual new cancer cases among women. Zambia is also experiencing a generalized
HIV epidemic, with HIV sero-prevalence rates of over 14% in the general adult population.
The HIV and cervical cancer epidemics intersect significantly, with HIV increasing the risk for
cervical cancer and worsening its prognosis. Several national and international efforts, includ-
ing those funded through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR),
have invested significant resources in upgrading Zambia’s capacity for prevention, care, and
treatment of HIV/AIDS over the past decade [16,17].
Prompted by pilot research that demonstrated a very high burden of ICC and high-grade
cervical precursors among HIV-infected Zambian women newly accessing antiretroviral thera-
py [18], we began an innovative Zambian-US partnership to initiate CCPPZ in 2006. PEPFAR,
through the U.S. Centers for Disease Control and Prevention (CDC), funded CCPPZ as its
first-ever cervical cancer prevention initiative focused on HIV-infected women. Local leader-
ship was provided by the Zambian Ministry of Health while program operations were managed
by the Center for Infectious Disease Research in Zambia (CIDRZ), a Zambian-US non-profit
organization, in collaboration with the Department of Obstetrics and Gynecology of the Uni-
versity of Zambia in Zambia. PEPFAR funding allowed us to initially offer services to the high-
est-risk HIV-infected women, but the development of the infrastructure and human resources
through this funding allowed the program to offer these services to all women in the catchment
area, regardless of their HIV status, with low marginal costs. Starting with two public sector
clinics in the country’s most populated province (Lusaka) in 2006, CCPPZ now operates in 33
government-run health facilities across all of Zambia’s 10 provinces [19–25]. (Fig 1) (Fig 2).
Adaptation of the cervical cancer screening intervention
Given the concerns about suboptimal sensitivity and lack of an efficient quality assurance
mechanism for VIA-based screening, we developed an innovative and locally adapted telecom-
munications matrix that provided single-visit point-of-care enhanced digital imaging of the
cervix (digital cervicography), peer review, quality assurance, continuing medical education,
objective record of screening test results, and access to expert opinion through immediate dis-
tance consultation, if needed [22]. (Fig 3) (Fig 4) Treatment decisions were made primarily on
the basis of VIA, however, if there were disagreements between VIA and cervicography, the lat-
ter was used to make the final decision.
Population-Level Scale-up of Cervical Cancer Prevention in Zambia
PLOS ONE | DOI:10.1371/journal.pone.0122169 April 17, 2015 3 / 19
Linking screening to treatment
To address the problem of patient adherence to treatment recommendations we tightly linked
screening to treatment in the form of a single-visit ‘screen-and-treat (freeze)’ approach for
cryotherapy-eligible lesions, and a two-visit ‘screen-referral-loop electrosurgical excision pro-
cedure (LEEP)’ approach (with no intervening punch biopsy except when the lesion is suspi-
cious for ICC) for cryotherapy-ineligible lesions. An acetowhite lesion was considered
cryotherapy-eligible if all the following criteria were fulfilled: the lesion involves three-fourths
or less of the cervix, does not extend into the endocervical canal, can be fully covered by the
cryoprobe, and has no clinical suspicion/evidence of invasive cancer. (Fig 4) Cryotherapy was
provided by trained nurses using a double freeze technique [26] operating independently in
public-sector primary care clinics located within the community. Women with complex cryo-
therapy-ineligible VIA positive lesions requiring LEEP/punch biopsy, as well as women with
other gynecologic disorders such as pelvic masses, vulvar lesions, cervical polyps, cervical myo-
mas, abnormal uterine bleeding, etc. were referred for physician evaluation at the University of
Zambia’s Gynecologic Cancer Prevention Unit. LEEP or punch biopsy was performed by
nurses and physicians in referral clinics, located in facilities equipped with a fully operational
surgical theatre in case of hemorrhage. Data were electronically captured at the point-of-care
by community health workers and nurses, and in case of HIV-infected women the data were
Fig 1. District-level expansion across provinces in Zambia (2006–2014) and projected (in 2016) of the Cervical Cancer Prevention Program in
Zambia (CCPPZ).
doi:10.1371/journal.pone.0122169.g001
Fig 2. Clinic-level expansion in the Lusaka province (2006–2014) of the Cervical Cancer Prevention Program in Zambia (CCPPZ).
doi:10.1371/journal.pone.0122169.g002
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also linked to Zambia’s unique, country-wide electronic medical record system for HIV/
AIDS care.
Adaptations for program expansion
VIA/cryotherapy-based ‘screen and treat’ service platforms were initially expanded into the 12
largest primary public health clinics within Lusaka, the country’s most heavily populated prov-
ince, with one referral clinic for LEEP and biopsy located at the University of Zambia [21,23].
An identical service platform (VIA/cryotherapy/LEEP) was placed in each of the remaining
nine provincial hospitals as well as the large district hospitals within each province. Prior to the
establishment of each service platform CCPPZ staff conducted a site visit to meet the Provincial
Health Officer, organize the logistics of community awareness and supply chain, and assess the
need for administrative, pathology, quality assurance, data collection and communication tech-
nology services. All healthcare providers were trained in the CCPPZ’s cervical cancer preven-
tion training program which provides two weeks of didactic and hands-on clinical-mentoring
in Lusaka clinics. Every 3 months, nurses from the Lusaka clinics visited facilities in the outly-
ing provinces for purposes of quality assurance and continued medical education. Pathology
(LEEP and punch biopsy) specimens were sent by courier to the pathology department at the
University of Zambia, the local provincial hospitals, or contracted out to private
sector pathologists.
Program outreach and community mobilization
From the inception of the program, community health workers and community mobilization
actions were central components of our health promotion and adherence efforts. Volunteer
women with an aptitude for voicing health concerns were selected from communities sur-
rounding their respective screening clinics and trained to conduct cervical health promotion
talks to women, to inform them of CCPPZ’s free, walk-in/same-day services using simple, but
persuasive, messaging. Women requesting more information or expressing a desire to be
screened were ‘navigated’ by these ‘peer educators’ to the CCPPZ clinics.
Process and outcome metrics
To evaluate the program operations and scale-up of CCPPZ’s services from 2006 to 2013, we
analyzed data from the CCPPZ electronic medical records database. We derived key process
and outcome metrics that reflected the success of CCPPZ’s prevention services and integration
and interaction with and beyond the HIV/AIDS program infrastructure. These metrics includ-
ed: (i) annual program uptake rate between 2006–2013 and comparison of year-on-year change
Fig 3. Performing VIA-based screening augmented by digital cervicography in the clinics of the
Cervical Cancer Prevention Program in Zambia (CCPPZ).Notes: Nurses in CCPPZ clinics initially
perform screening using VIA, after which they use a commercial brand (off-the-shelf) hand-held digital
camera (Upper Panel) to take photographs of the cervix (cervigrams). Cervigrams are then displayed on a
bedside television or camera monitor in real-time (Middle Panel), permitting magnification and detailed
examination of lesion morphology, including size, margin sharpness, proximity to the transformation zone,
degree of extension into the endocervical canal, abnormal vasculature (mosaicism, punctations, atypical
blood vessels) and gross characteristics suspicious for ICC. Cervigrams are routinely shown to and
discussed with patients during the screening procedure after which they are uploaded by nurses to a clinic
computer where they can be (i) electronically transmitted using cellphone network lines to off-site experts
(after deidentifcation) for rapid distance consultation (telecervicography), when necessary, (ii) batched and
later routinely peer reviewed to form the basis of a rigorous ongoing continuing education and quality
assurance program, and (iii) stored with the patient’s electronic medical record. Relevant cervigrams are
transmitted by screening nurses to the referral clinic by email, after deidentification, where they are
accessible by consultants at the time of patient visits. (Lower Panel).
doi:10.1371/journal.pone.0122169.g003
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Fig 4. Images of VIA negative, VIA positive-cryotherapy eligible and VIA positive-cryotherapy ineligible lesions fromwomen undergoing screening
in the Cervical Cancer Prevention Program in Zambia (CCPPZ). Notes: Using the following criteria, CCPPZ nurses classify VIA tests results as VIA
negative, VIA positive eligible for local ablation with cryotherapy, or VIA positive ineligible for cryotherapy requiring physician evaluation.
• VIA negative: Absence of an acetowhite lesion with at least one distinct border (Top Panel, Left)
• VIA positive, eligible for cryotherapy: Acetowhite lesion with at least one distinct border, located within or adjacent to the transfor-
mation zone, that: occupies<75% or<3 quadrants of the surface of the ectocervix, is completely visualized, can be completely covered
Population-Level Scale-up of Cervical Cancer Prevention in Zambia
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and differences by age categories and HIV status; these were derived from comparisons of rela-
tive proportions and changes in age and HIV-strata over time relative to total women screened,
(ii) rates and trends in screening positivity and cryotherapy: comparison of changes over time
of the proportion of women screening positive (defined as being screen-positive on either VIA
or cervicography, out of the total number of women screened) and those receiving cryotherapy
(among total women screened and among women screening positive) and differences by age
category groups and HIV status, (iii) proportion of women receiving treatment on the same
day of screening (the ‘screen-and-treat’ approach) among screen-positive women that received
cryotherapy treatment, (iv) differences in rates of histopathologic detection of cervical precan-
cer (cervical intraepithelial neoplasia grades 2/3 [CIN2/3]) and ICC by HIV status and age cat-
egories, and programmatic yield by histopathologic diagnoses, (v) trends in provision of ‘same-
day services’ (i.e., proportion of screen-positive women who underwent same-day cryotherapy
plus women who had a screening-negative result, out of total women screened) and rates of
confirmed CIN2+ (CIN2/3 and ICC) diagnoses among women referred for histopathologic
evaluation, (vi) differences in screening positivity rates and rates of treatment of cervical pre-
cancer by HIV status.
This outcomes evaluation study of anonymized patient records of a public sector implemen-
tation program was deemed exempt from human subjects review or the need for informed con-
sent by the Research Ethics Committee of the University of Zambia.
Results
Program uptake and socio-demographics and HIV status of women
undergoing screening
A total of 108,330 women were offered screening in 12 public sector clinics in the Lusaka prov-
ince in Zambia between January 2006 and December 2013, of whom 102,942 (95%) underwent
screening. The absolute number of women undergoing screening increased significantly with
every calendar year (p-trend<0.001). The socio-demographic and sexual-reproductive charac-
teristics of these women are shown in Table 1. The vast majority (72%) of women attending
the screening were between the ages of 25–49 years, i.e., the target age for screening. The rela-
tive composition of age-groups of the screened populations remained relatively stable across
the screening period of 2006–2013. Almost half (45%) of the women reported their monthly
household income being less than 500,000 Zambian Kwacha (approximately equivalent to US
Dollars 80/month), and almost two-thirds (67%) had never completed a high-school
by the largest available cryoprobe tip, has no evidence of abnormal vasculature (punctations, mosaicism, atypical blood vessels) and is
not suspicious for ICC (Top panel, right)
• VIA positive, ineligible for cryotherapy: Acetowhite lesion with at least one distinct border, located within or adjacent to the transfor-
mation zone, that has any of the following characteristics:
• Occupies 3 quadrants or75% of the surface of the ectocervix (Middle panel, left)
• Has evidence of abnormal vasculature (punctations, mosaicism, atypical blood vessels) (Middle panel, center)
• Cannot be completely covered by the largest available cryoprobe tip (Middle panel, right)
• Is suspicious for invasive cervical cancer (Bottom panel, left)
• Extends into the endocervical canal beyond complete visualization (Bottom panel, right)
doi:10.1371/journal.pone.0122169.g004
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Table 1. Socio-demographic and sexual and reproductive characteristics of participants in the Cervi-
cal Cancer Prevention Program in Zambia (CCPPZ) during 2006–2013.
Characteristics Number Percentage
Women attending screening clinics 108,330










No formal education 3,998 4.8
Some primary education 14,215 17.0
Primary school completed 14,743 17.6
Some high school completed 23,275 27.8




Formal sector 16,969 21.4
Informal sector 23,623 29.8
Others 10,649 13.5







Never married 10,534 15.9
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education. Just under half reported their first sexual intercourse at age 17 or less, and almost
three-quarters (74%) reported having multiple (2+) lifetime sexual partners. A large majority
(80%) had multiple (2 or more) pregnancies, and almost one-third (30%) had 5 or more preg-
nancies. A very tiny minority (1.8%) had ever been screened with Pap smears for
cervical cancer.
Overall, just over a quarter of women screened were HIV-positive (28%; 28,529/102,942),
about half were HIV-negative (48%; 49,483) and the HIV status was unknown in about a quar-
ter of the women (24%; 24,930). The proportion of HIV-positive women among the total
screened population declined from 55% in 2006 to 26% in 2013, while the proportion of
women who were HIV-negative increased during the same period from 23% to 56% (Fig
5-Panel A). The proportion of women whose HIV status was unknown initially increased from
22% in 2006 to 35% in 2007, but as HIV testing services began being offered in the cervical can-
cer screening clinics, this proportion steadily fell, and was 19% in 2013.
Rates of screening-positivity and cryotherapy by age
Among the 102,942 women screened, 1,075 (1%) had uncertain VIA results (Table 2). Of the
remaining 101,867 with conclusive screening results, 20,419 (20%) were screen-positive. The
screen positivity rate differed by age and HIV-status and was highest (23%) among women be-
tween 30–39 years and lowest (12%) among women>50 years (Fig 5-Panel B). The overall
screen-positivity rate fell significantly from 45% in 2006 to 12% in 2013 (p-trend<0.001) (Fig
5-Panel C) and the decline was consistent across HIV-status (data not shown).
A total of 11,508 (56%, out of 20,419 VIA screen-positive) women received cryotherapy,
and 8,911 (44%) were referred for further evaluation for cryotherapy-ineligible lesions to the
referral clinic at the University of Zambia (Table 2). The rate of cryotherapy (11%, expressed
as a proportion of total number of women screened) declined with age (p<0.001) (Fig 5-Panel
B) and with calendar year (31% in 2006 to 6% in 2013, p-trend<0.001) (Fig 5-Panel C). The
rate of cryotherapy as a proportion of VIA positive women was highest (65%) among women
<30 years, and proportionally decreased with age (56% among women 30–39 years, 46% in
women 40–49 years, and only 24% in women>50 years) (p-trend<0.001).
Of the 7,527 screen-positive women treated with cryotherapy who had complete informa-
tion on screening and treatment dates, over two-thirds (65%, 4,853) had treatment on the same
day of screening and almost 80% (78.6%, 5,912) within one week of screening (Table 2). These
proportions were similar across different HIV status categories.
Rates of histopathologically-confirmed cervical precancer and cancer
Among 8,911 screen-positive women referred for physician evaluation, 4,819 (54%) complied
with the referral to the University of Zambia (Table 2). Among those who complied with refer-
ral, histopathology results were available for 3,938 (81.7%) women (denominator for this anal-
ysis), of which ICC was present in 710 (18%), CIN2/3 lesions were present in 1,025 (26%),
Table 1. (Continued)
Characteristics Number Percentage
Ever had Pap smear
No 94,690 98.2
Yes 1,755 1.8
* 1 US dollar = 6,430 Zambian Kwacha (ZMK; using pre-2013 currency base)
doi:10.1371/journal.pone.0122169.t001
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while 2,203 (56%) women hadCIN1 lesions. Overall, among women with ICC, 53% were
HIV-positive, 27% were HIV-negative and 20% were of unknown-HIV status, while among
women with CIN2/3 lesions, the corresponding prevalence of HIV-positive, HIV-negative, and
HIV-unknown status was 71%, 18% and 11%, respectively (Table 3). Approximately half
(50.3%, 357) of the 710 cases of ICC were diagnosed in screen-positive women whose lesions
were evaluated with LEEP, as they were cryotherapy-ineligible but not grossly suspicions for in-
vasion, the latter which were diagnosed with punch biopsy (Table 3).
Over the eight-year period (2006–2013), among every 1,000 women who underwent screen-
ing, 10 (95%CI: 9.4–10.6) were detected with histologically-confirmed CIN2/3 lesions, and 6.9
(95%CI: 6.5–7.5) were detected with histologically-confirmed ICC (Table 3). In other words,
the nurse-led ‘screen-referral-LEEP’ approach led to the detection of one case of CIN2/3 for
every 100 women screened, one case of ICC for every 145 (95%CI: 121–172.8) women
screened, or one case of CIN2+ (precancer or cancer) among every 59.3 (95%CI: 51.7–77.0)
women screened (Table 3). Annualizing the cumulative detection rates into an incidence rate,
the histologically-proven detection alone would approximately equate to an annual rate of 117/
100,000 women (albeit with substantial differences in rates by HIV status [Table 3]), which is
more than twice than the present IARC/WHO-reported ICC rate of 58.4/100,000 in Zambia.
Fig 5. Program process and outcome indicators of the Cervical Cancer Prevention Program in Zambia (CCPPZ). Panel A (Top, left): Trends in HIV
status of screened women over the calendar years 2006–2013. Panel B (Bottom, left): Rates of screening positivity, cryotherapy eligibility and cryotherapy-
ineligiblity by age categories and overall. Panel C (Bottom, right): Trends in rates of screening positivity and cryotherapy rates over calendar years 2006–
2013. Panel D (Top, right): Trends in rates of ‘same day-services’ and rates of ‘appropriate referral’ over calender years 2006–2013.
doi:10.1371/journal.pone.0122169.g005
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Trends in rates of provision of ‘same-day services’ and
histopathologically-confirmed cervical precancer and cancer
Overall, among the 98,961 (102,942 screened minus 3,981 screen-positives treated with cryo-
therapy who had missing information on screening and/or treatment dates) women with com-
plete screening data, the program provided ‘same-day services’ to a total of 86,301 (87%)
women, which included 4,853 (5%) screen-positives who underwent same-visit cryotherapy
Table 2. Programmatic processmeasures (screening and treatment uptake by HIV status) in the Cervical Cancer Prevention Program in Zambia
(CCPPZ).
HIV-positive HIV-negative HIV-unknown Total
n (%) n (%) n (%) n (%)
Women screened 28,529 49,483 24,930
102,942
Women with uncertain screening results* 368 (1.3) 415 (0.8) 292 (1.2) 1,075
(1.0)
Women with satisfactory screening results 28,161 49,068 24,638
101,867
Screen-positives** 8,961 (31.8) 6,840 (13.9) 4,618 (18.7)
20,419 (20.0)
Screen-positives treated with cryotherapy at clinics$† 4,289 (47.9) 4,463 (65.2) 2,756 (59.7)
11,508 (56.4)
Screen-positives referred to UTH$ 4,672 (52.1) 2,377 (34.8) 1,862 (40.3) 8,911
(43.6)
Screen-positives that attended UTH for referral¥ 2,851 (61.0) 1,238 (52.1) 730 (39.2) 4,819
(54.1)
Screen-positives that received LEEP$† 2,208 (24.6) 798 (11.7) 462 (10.0) 3,468
(17.0)
Screen-positives that received any form of treatment (cryotherapy/LEEP) $† 6,126 (68.4) 5,080 (74.3) 3,152 (68.3)
14,358 (70.3)
Time interval between screening and cryotherapy
Screen-positives treated with cryotherapy (with complete data on screening and
treatment dates)
2,810 2,951 1,766 7,527
Cryotherapy on same day as screening§ 1,835 (65.3) 1,903 (64.5) 1,115 (63.1) 4,853
(64.5)
Cryotherapy  one week after screening§ 349 (12.4) 423 (14.3) 288 (16.3) 1,060
(14.1)
Cryotherapy > one  four weeks after screening§ 210 (7.5) 197 (6.7) 130 (7.4) 537 (7.1)
Cryotherapy > four weeks after screening§ 416 (14.8) 428 (14.5) 233 (13.2) 1,077
(14.3)
HIV: HIV: human immunodeficiency virus; UTH: University of Zambia;
* Proportion out of women screened;
** Proportion out of women with satisfactory screening results;
$ Proportion out of screen-positives;
¥ Proportion out of screen-positives referred to UTH;
§ Proportion out of screen-positive women treated with cryotherapy that had complete data on screening and/or treatment dates;
† Some women received both LEEP and cryotherapy; hence these categories are not mutually exclusive.
doi:10.1371/journal.pone.0122169.t002
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and 81,448 (82%) who were VIA-negative and were counselled about their risk and advised fol-
low-up after 3–5 years (if HIV-negative) and annual follow-up (if HIV-positive). The rate of
‘same day services’ increased between 2006 and 2013 from 88% to 94% (p<0.001) (Fig 5-Panel
D). In effect, only one in ten women undergoing screening is required to undertake a second
visit (to a referral facility). Among women who underwent histopathologic evaluation, the
overall rate of CIN2+ lesions was 44.1% (1,735/3,938). This rate improved significantly from
41% in 2006 to 48% in 2013 (p-trend<0.001) (Fig 5-Panel D).
Differences in screening positivity, treatment and referral rates, and
histologically-confirmed CIN2+ rates by HIV status
Women with HIV were twice as likely to be detected as VIA-positive than HIV-negative
women (31.8% vs. 13.9%, crude relative risk [RR]: 2.9, 95% CI = 2.8–3.0, p<0.001). Among
VIA screen-positive women, as compared to HIV-negative women, women with HIV were less
likely to be treated by cryotherapy (48% vs. 65%, crude RR: 0.73, 95% 0.71–0.75, p<0.001),
more likely to be referred to UTH for histologic evaluation of cryotherapy-ineligible lesions
(52% vs. 34%, crude RR: 1.5, 95% 1.4–1.6, P<0.001), and more likely to have histologically-
confirmed CIN2+ (i.e., CIN2/3 and ICC) lesions (47.1% vs. 37.9%, crude RR: 1.5, 95%
CI = 1.3–1.7, p<0.001).
Table 3. Programmatic outcomemeasures (cervical intraepithelial neoplasia and invasive cancers detected among screen-positives by HIV sta-
tus) in the Cervical Cancer Prevention Program in Zambia (CCPPZ).
HIV-Positive HIV-Negative HIV-Unknown Total
(n = 28,529) (n = 49,483) (n = 24,930) (n = 102,942)
CIN and ICC cases detected among women with histopathology results^
CIN 1, n (% of all CIN 1) 1,237 (56.2) 616 (28.0) 350 (15.9) 2,203 (100)
CIN 2/3, n (% of all CIN 2/3) 724 (70.6) 187 (18.2) 114 (11.1) 1,025 (100)
ICC, n (% of all ICC) 376 (53.0) 189 (26.6) 145 (20.4) 710 (100)
CIN2+, n (% of all CIN2+) 1100 (63.4) 376 (21.7) 259 (14.9) 1735 (100)
CIN and ICC cases diagnosed from women undergoing LEEP*
CIN 1, n (% of all CIN 1) 1,005 (57.7) 478 (27.4) 260 (14.9) 1,743 (100)
CIN 2/3, n (% of all CIN 2/3) 658 (72.1) 156 (17.1) 98 (10.7) 912 (100)
ICC, n (% of all ICC) 235 (65.8) 70 (19.6) 52 (14.6) 357 (100)
CIN2+, n (% of all CIN2+) 893 (70.4) 226 (17.8) 150 (11.8) 1,269 (100)
No. of CIN and ICC cases detected per 1000 women screened^
CIN 1, n (95%CI) 43.4 (41.1–45.8) 12 (11.5–13.5) 14 (12.7–15.6) 21 (20.5–22.3)
CIN 2/3, n (95%CI) 25.4 (23.6–27.3) 3.8 (3.3–4.4) 4.6 (3.8–5.5) 10 (9.4–10.6)
ICC, n (95%CI) 13.4 (12.1–14.8) 3.8 (3.3–4.4) 5.8 (4.9–6.8) 6.9 (6.5–7.5)
CIN2+, n (95%CI) 38.6 (36.4–40.9) 7.6 (6.9–8.4) 10.4 (9.2–11.7) 16.9 (16.1–17.7)
No. of women screened to detect one case of CIN and ICC^
CIN 1, n (95%CI) 23.1 (16.1–33.0) 80.3 (61.4–104.5) 71.2 (48.7–103.1) 46.7 (38.7–56.4)
CIN 2/3, n (95%CI) 39.4 (27.5–56.2) 264.6 (206.6–332.1) 218.7 (152.7–303) 100.4 (83.5–120.4)
ICC, n (95%CI) 75.9 (53.2–107.1) 261.8 (204.3–328.8) 171.9 (119.2–241.6) 145 (121–172.8)
CIN2+, n (95%CI) 25.9 (18.1–37.1) 131.6 (101.1–169.5) 96.3 (66.0–138.3) 59.3 (51.7–77.0)
HIV: human immunodeficiency virus; CIN: cervical intraepithelial neoplasia; LEEP: loop electrosurgical excision procedure, ICC: invasive cervical cancer;
^Histopathology results were available among 3,938 women,
* Histopathology results were available from 3,012 LEEP specimens
doi:10.1371/journal.pone.0122169.t003
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Discussion
The results of this programmatic evaluation demonstrate that VIA-based screening services
can be scaled-up at a population-level when adopted as part of the routine health care system
in a low-resource, high disease burden country. Cervical cancer prevention services can benefit
by efficient linkages with HIV/AIDS care and treatment services and, with time, such services
can be offered to all women at need, regardless of HIV status. Our evaluation shows that the
operational efficiency of the program as measured by rates of ‘same-day services’ and histo-
pathologically-confirmed precancer and cancer improves with experience and sustained efforts
in quality improvement. Setting-specific challenges in implementation can be overcome with
locally-developed solutions, particularly with sufficient political will and stakeholder support.
The findings emanating from this implementation research study could provide stimulus for
replicating such national-level program expansions in sub-Saharan Africa, as well as in other
resource-constrained settings globally. Although the cervical screening program in Zambia
heavily relied on the HIV care infrastructure for implementation and scaling-up, the broader
lesson for settings with a lesser HIV burden is that cervical screening services can be successful-
ly developed and scaled-up in routine public health services by innovative integration with
other vertical health initiatives.
Our study has highlighted the substantially high burden of histologically-confirmed precan-
cerous and cancerous (CIN2+) lesions that is uncovered by the establishment of a population-
based screening program. It exemplifies the critical need for investments in oncologic surgery
and radiation therapy alongside screening platforms, in order to avoid unnecessary deaths, suf-
fering, and social consequences of detected but untreated disease. It also underscores the im-
portance of continued global efforts to expand HPV vaccination.
A retrospective critique and evaluation suggests six distinguishing facets of this program
that contributed to the success of the scale-up of the implementation.
First, the leveraging of the momentum and resources of an ongoing, funded vertical health
initiative (HIV care and treatment) allowed the development of capacity for the prevention of a
non-communicable disease (cervical cancer). Focusing on the provision of services for high-
risk HIV-infected women initially allowed a firm rooting of our program and provided a foun-
dation for sustainability, but did not hamper or preclude eventual wider expansion of services
to the general (HIV-uninfected) women in the community, as evidenced by the increasing pro-
portion of HIV-negative women over the program expansion period (Fig 5-Panel A). Using
existing infrastructures for implementing screening can only help in the long-run in terms of
costs, expertise and sustainability.
Second, we adapted the screening intervention to local circumstances instead of rigorously
retrofitting approaches that are successful, but in radically different environments. While our
approach of screening promoted task shifting (doctors to nurses), we harnessed the power of
mobile technology to address human resource gaps by allowing distance consultation to im-
prove clinical decision making. Embedding the basic principle of cervical cancer prevention
with visual-based screening in a public health context and linking the initial encounter within a
matrix of an affordable and locally available telecommunications technology (‘electronic cervi-
cal cancer control—eC3’) allowed us to roll-out standardized, quality-assured, cervical cancer
screening and real-time distance consultation at remote sites across Zambia where it would
never have been possible before [22].
Third, we heavily invested in a surgical excision (LEEP) infrastructure and expanded diag-
nostic services to facilitate management of complex cervical lesions that exceeded the therapeu-
tic limitations of cryotherapy. The diagnosis and treatment of complex cervical lesions not
amenable to local ablation by cryotherapy is as critical as, if not more than, providing same-
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visit screen-and-treat services for cryotherapy-eligible lesions. This was particularly critical for
HIV-positive women who were more likely to require referral for histologic evaluation than
HIV-negative women. Screening without linkages to treatment is unethical, hence both ‘single-
visit screen-and-treat’ and ‘screen-referral-LEEP’ were frontline components of our compre-
hensive cervical cancer prevention program. The surgical excision component was a part of the
initial programmatic vision itself and not an after-thought. This ensured that treatment of pre-
cancerous lesions was feasible for both low- and high-grade precancerous lesions, as reflected
by the fact 70% of screen-positive women who were eligible for treatment received it. It also
provided the basis for evaluating the most critical histologic outcomes (i.e., CIN2+) for moni-
toring programmatic impact. LEEP also served the dual purpose of diagnosis and treatment for
the vast majority of women diagnosed with CIN3 or more severe lesions such as preclinical, oc-
cult invasive cancer.
Fourth, we constantly assessed all phases of the program through a rigorous process of mon-
itoring and evaluation of interim outcomes. Our use of routine programmatic indicators (e.g.,
screening uptake rates by age and HIV status, rates of cryotherapy-ineligible lesions, screening
positivity and CIN2+ detection rates by age and HIV status, rates of ‘same day services’ and
‘appropriate referrals’) provided ongoing evidence on the role of improvements in the quality
of screening and treatment services over time [19,25]. For instance, the VIA positivity rate
dropped from 45% to less than 15% over an 8-year period indicating the learning curve of the
providers following supervision and field monitoring [19]. Similar impact of the learning curve
of the test providers and field supervision on VIA positivity rates over time has been demon-
strated in other studies as well [7–11,27,28]. These process and outcomes indicators were
among the only clinical effectiveness metrics in the absence of a well-functioning population-
based cancer registry and/or a widely-used national-level citizen identification system to mea-
sure declines in cancer incidence over time.
Fifth, we strengthened the existing healthcare delivery system as we gathered evidence and
assessed needs, on-the-go, as an innovative approach to sustainability and long-term success.
Whether to immediately implement cervical cancer prevention services with meagre resources,
or working first to develop well-functioning health systems, was no longer an issue for debate.
We arrived at innovative solutions (Table 4) to overcome critical programmatic challenges
posed by the less-than-optimal existing public health infrastructure, all while providing the ex-
pansion of service provision activities. These approaches to problem-solving provide some of
the very few, if any, ‘hands-on’ examples for implementing similar programs in resource con-
strained settings. They reflect the product of critical thinking by a close knit team of pragmatic
clinicians (doctors and nurses) and public health program staff, consisting of Zambian nation-
als and an expatriate U.S. board-certified gynecologic oncologist (GPP) living within the coun-
try, and represent vital and intermediate steps in the development and sustenance of efficient
healthcare delivery systems in such settings.
Sixth, women detected with invasive cervical cancer are treated with radical surgery or
megavoltage radiotherapy/chemoradiotherapy at the national cancer center in Lusaka (Cancer
Diseases Hospital). This matrix type of cancer center has been organized by the Zambian gov-
ernment at the University of Zambia Teaching Hospital in close proximity to and interaction
with pathology, diagnostic imaging and other tertiary care services in the teaching hospital that
permits comprehensive cancer diagnosis and treatment services for cancer patients within
the country.
In collaboration with the Zambian government (Ministry of Health, Ministry of Communi-
ty Development, Mother and Child Health, and the University of Zambia), CCPPZ presently
(September 2014) supports 33 ‘screen and treat’ clinics and 18 LEEP clinics located throughout
the country’s 10 provinces (Fig 1) (Fig 2). According to national cervical cancer control plans
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Table 4. Critical Problems and Practical Local Solutions in the Cervical Cancer Prevention Program in Zambia (CCPPZ) (list not exhaustive, for il-
lustrative purposes only).
Problem(s) Practical solution Impact
Weak opportunistic cytology-based cervical cancer
screening infrastructure in the pubic system; no
source of independent funding for cervical cancer
prevention
Horizontal integration of a cervical cancer prevention
intervention into a pre-existing HIV care and treatment
infrastructure; VIA as the main approach
Facilitated population-level
implementation and scale-up of
intervention
High cost of colposcopy; no quality assurance for
VIA
Introduction of innovation: “electronic cervical cancer
control”—eC3
Reduction in over and under treatment
Shortage of gynecologists to provide expert opinion Web consultation: Immediate access to physician
opinion through telemedicine
Access to clinical expert for decision
making
Low level of community awareness; myths and
misconceptions about cervical cancer
Used peer educators and traditional social, political
and medical infrastructures for health promotion
Increased patient uptake
Paper records not managed well Point-of-care electronic data collection More efficient and secure data system
Pathology bottleneck (delays in results reporting due
to unavailability of pathology services)
Liaison with UTH pathology department; “one off”
supplementation of supplies; use of private sector
pathology services
Efficiency of pathology services
significantly improved
Chemoradiation unavailability/ referral challenges Formal Organizational Linkages with the National
Cancer Centre in Lusaka
More efficient referrals
Bottleneck of early stage cervical cancer cases
requiring radical surgery
Established gynecologic oncology surgical service in
public and private sector
Slight relief of bottleneck
Complex acetowhite lesions ineligible for cryotherapy Developed capacity for loop electrosurgical excision
procedure (LEEP)
Ability to evaluate and treat cryotherapy-
ineligible lesions
Deficit of cervical cancer prevention clinicians Local training program for nurses and doctors Increased supply of clinical personnel
Reluctance of women undergoing screening, with
unknown HIV status, to be tested in nearby HIV care
and treatment clinics
Implemented HIV counseling and testing within “screen
and treat” clinics, by screening nurses
Marked increase in HIV testing rates
Management of microinvasive cancers in young
women desirous of fertility potential
Developed algorithm for conservative management of
women with microinvasive cancer
Avoidance of unnecessary loss of
fertility
Unreliable and insecure procurement, storage and
distribution of equipment and supplies
Hiring of Procurement Officer and procurement system Efficient and secure procurement
system
Lack of local ownership Persistent mentoring of Zambians at all levels of
leadership; Integration of “screen and treat” service
platforms in government-operated clinics; Limiting role
of CIDRZ to “technical assistance”
Increased ownership by Ministry of
Health, Ministry of Community
Development, Mother and Child Health
Increased demand for services, particularly in rural
areas
Implementation of outreach program in the form of
village-based screening camps; Training of a cadre of
trainers, i.e., TOTs
Rapid expansion of services into rural
areas
High cost and unreliable supply of compressed gas
leading to frequent interruptions of services
Use of alternative local ablation strategies, i.e., cold
coagulation and Cryopen
Uninterrupted “screen and treat services
Lack of available local leadership to champion the
cause of cervical cancer prevention
CIDRZ supported full-time, on-the-ground support for
U.S. gynecologic oncologist
Program initiated
Inefficient management Creation of management infrastructure and
stratification of organization into separate units:
administrative, health promotions, clinical, information
communication technology (ICT) and quality
improvement.
Improved efficiency
Limited funding for programmatic innovations Participation in international student intern and
fellowship programs, e.g., Fogarty, Global Health Corp
Support for innovative developments
Evaluation of programmatic outcomes Development of an all-electronic database of screening
results, key sociodemographic and sexual and
reproductive history covariates; linked to histologically-
confirmed results
Improved assessment of programmatic
impact
doi:10.1371/journal.pone.0122169.t004
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there will be 100 ‘screen and treat’ clinics and 20 LEEP clinics by December 2016. Nevertheless,
the present model of establishing ‘screen and treat’ clinics in government-operated stationary
public health facilities has only made incremental gains in terms of women screened per
annum. A recent analysis of our programmatic data revealed that using our present model, as-
suming an increase in patient uptake of 10% per annum, it would require 17 additional years to
reach the target population of 1.5 million Zambian women.
We have thus embarked upon a phase of screening which is intended to facilitate a radical
and exponential uptake of services. The Zambian government has (as of March 2015) officially
adopted CCPPZ as its national cervical cancer prevention program and it will be administered
out of the Ministry of Health. Building on our present clinic infrastructure and telecommunica-
tions matrix it will focus on the provision of services in an outreach context and will include
screening camps and village-based screening in collaboration with Ministry of Chiefs and Tra-
ditional Affairs, with local chiefs and chieftainesses, traditional marriage counsellors and tradi-
tional healers as primary advocates and facilitators. This new approach continues our use of
the philosophy of adaptive innovation which, in principle, incorporates respect for local beliefs
and culture while integrating new ideas and technology that fit the local circumstances.
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